Cargando…
Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue
PURPOSE: To investigate the short-term cerebral metabolic effects of intravenous chemotherapy and their association with long-term fatigue/cognitive complaints. EXPERIMENTAL DESIGN: Using [(18)F]-FDG-PET/CT whole-body scans, we retrospectively quantified relative cerebral glucose metabolism before a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612406/ https://www.ncbi.nlm.nih.gov/pubmed/36313711 http://dx.doi.org/10.3389/fonc.2022.1021615 |
_version_ | 1784819767245275136 |
---|---|
author | Schroyen, Gwen Schramm, Georg Van Weehaeghe, Donatienne Leenaerts, Nicolas Vande Casteele, Thomas Blommaert, Jeroen Koole, Michel Smeets, Ann Van Laere, Koen Sunaert, Stefan Deprez, Sabine |
author_facet | Schroyen, Gwen Schramm, Georg Van Weehaeghe, Donatienne Leenaerts, Nicolas Vande Casteele, Thomas Blommaert, Jeroen Koole, Michel Smeets, Ann Van Laere, Koen Sunaert, Stefan Deprez, Sabine |
author_sort | Schroyen, Gwen |
collection | PubMed |
description | PURPOSE: To investigate the short-term cerebral metabolic effects of intravenous chemotherapy and their association with long-term fatigue/cognitive complaints. EXPERIMENTAL DESIGN: Using [(18)F]-FDG-PET/CT whole-body scans, we retrospectively quantified relative cerebral glucose metabolism before and after neoadjuvant chemotherapy in a cohort of patients treated for non-metastatic breast cancer (2009-2019). Self-report of cognitive complaints and fatigue were prospectively assessed 7 ± 3 years after therapy. Metabolic changes were estimated with i) robust mixed-effects modelling in regions-of-interest (frontal, parietal, temporal, occipital, and insular cortex) and ii) general-linear modelling of whole-brain voxel-wise outcomes. iii) The association between metabolic changes and self-reported outcomes was evaluated using linear regression-analysis. RESULTS: Of the 667 screened patients, 263 underwent PET/CT before and after chemotherapy and 183 (48 ± 9 years) met the inclusion criteria. After chemotherapy, decreased frontal and increased parietal and insular metabolism were observed (|ß|>0.273, p(FDR) <0.008). Separately, additional increased occipital metabolism after epiribucin+ cyclophosphamide (EC) and temporal metabolism after EC+ fluorouracil chemotherapy were observed (ß>0.244, p(FDR) ≤0.048). Voxel-based analysis (p(cluster-FWE) <0.001) showed decreased metabolism in the paracingulate gyrus (-3.2 ± 3.9%) and putamen (3.1 ± 4.1%) and increased metabolism in the lateral cortex (L=2.9 ± 3.1%) and pericentral gyri (3.0 ± 4.4%). Except for the central sulcus, the same regions showed changes in EC, but not in FEC patients. Of the 97 self-reported responders, 23% and 27% experienced extreme fatigue and long-term cognitive complaints, respectively, which were not associated with metabolic changes. CONCLUSION: Both hyper- and hypometabolism were observed after chemotherapy for breast cancer. Combined with earlier findings, this study could support inflammatory mechanisms resulting in relative hypermetabolism, mainly in the parietal/occipital cortices. As early metabolic changes did not precede long-term complaints, further research is necessary to identify vulnerable patients. |
format | Online Article Text |
id | pubmed-9612406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96124062022-10-28 Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue Schroyen, Gwen Schramm, Georg Van Weehaeghe, Donatienne Leenaerts, Nicolas Vande Casteele, Thomas Blommaert, Jeroen Koole, Michel Smeets, Ann Van Laere, Koen Sunaert, Stefan Deprez, Sabine Front Oncol Oncology PURPOSE: To investigate the short-term cerebral metabolic effects of intravenous chemotherapy and their association with long-term fatigue/cognitive complaints. EXPERIMENTAL DESIGN: Using [(18)F]-FDG-PET/CT whole-body scans, we retrospectively quantified relative cerebral glucose metabolism before and after neoadjuvant chemotherapy in a cohort of patients treated for non-metastatic breast cancer (2009-2019). Self-report of cognitive complaints and fatigue were prospectively assessed 7 ± 3 years after therapy. Metabolic changes were estimated with i) robust mixed-effects modelling in regions-of-interest (frontal, parietal, temporal, occipital, and insular cortex) and ii) general-linear modelling of whole-brain voxel-wise outcomes. iii) The association between metabolic changes and self-reported outcomes was evaluated using linear regression-analysis. RESULTS: Of the 667 screened patients, 263 underwent PET/CT before and after chemotherapy and 183 (48 ± 9 years) met the inclusion criteria. After chemotherapy, decreased frontal and increased parietal and insular metabolism were observed (|ß|>0.273, p(FDR) <0.008). Separately, additional increased occipital metabolism after epiribucin+ cyclophosphamide (EC) and temporal metabolism after EC+ fluorouracil chemotherapy were observed (ß>0.244, p(FDR) ≤0.048). Voxel-based analysis (p(cluster-FWE) <0.001) showed decreased metabolism in the paracingulate gyrus (-3.2 ± 3.9%) and putamen (3.1 ± 4.1%) and increased metabolism in the lateral cortex (L=2.9 ± 3.1%) and pericentral gyri (3.0 ± 4.4%). Except for the central sulcus, the same regions showed changes in EC, but not in FEC patients. Of the 97 self-reported responders, 23% and 27% experienced extreme fatigue and long-term cognitive complaints, respectively, which were not associated with metabolic changes. CONCLUSION: Both hyper- and hypometabolism were observed after chemotherapy for breast cancer. Combined with earlier findings, this study could support inflammatory mechanisms resulting in relative hypermetabolism, mainly in the parietal/occipital cortices. As early metabolic changes did not precede long-term complaints, further research is necessary to identify vulnerable patients. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9612406/ /pubmed/36313711 http://dx.doi.org/10.3389/fonc.2022.1021615 Text en Copyright © 2022 Schroyen, Schramm, Van Weehaeghe, Leenaerts, Vande Casteele, Blommaert, Koole, Smeets, Van Laere, Sunaert and Deprez https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Schroyen, Gwen Schramm, Georg Van Weehaeghe, Donatienne Leenaerts, Nicolas Vande Casteele, Thomas Blommaert, Jeroen Koole, Michel Smeets, Ann Van Laere, Koen Sunaert, Stefan Deprez, Sabine Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue |
title | Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue |
title_full | Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue |
title_fullStr | Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue |
title_full_unstemmed | Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue |
title_short | Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue |
title_sort | cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612406/ https://www.ncbi.nlm.nih.gov/pubmed/36313711 http://dx.doi.org/10.3389/fonc.2022.1021615 |
work_keys_str_mv | AT schroyengwen cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT schrammgeorg cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT vanweehaeghedonatienne cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT leenaertsnicolas cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT vandecasteelethomas cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT blommaertjeroen cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT koolemichel cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT smeetsann cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT vanlaerekoen cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT sunaertstefan cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue AT deprezsabine cerebralglucosechangesafterchemotherapyandtheirrelationtolongtermcognitivecomplaintsandfatigue |